Published date: 29 January 2021

This notice was replaced on 23 April 2021

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Awarded contract (published 23 April 2021)

Awarded contract - This means that the contract has been awarded to a supplier.


Contract summary

Industry

  • Vaccines - 33651600

Location of contract

United Kingdom, Channel Islands, Isle of Man

Value of contract

£0

Procurement reference

CF-0102100D0O000000rwimUAA2

Published date

29 January 2021

Closing date

9 September 2020

Closing time

12am

Contract start date

1 April 2021

Contract end date

31 March 2025

Contract type

Supply contract

Procedure type

Negotiated procedure without prior publication (above threshold)

The opportunity was not advertised, because for example only one supplier is capable of delivering the requirement, or due to extreme urgency brought about by unforeseen events.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No


Description

The provision of herpes zoster (shingles) vaccine(recombinant, adjuvanted) deliveries will be required from 1 April 2021 to 31 March 2023, with an option to extend for up to an additional 24 months.


Award information

Awarded date

16 December 2020

Contract start date

1 April 2021

Contract end date

31 March 2025

Total value of contract

£66,131,483

This contract was awarded to 1 supplier.

GlaxoSmithKline UK Ltd - Vaccines

Address

980 Great West Road
Brentford, Middlesex Tw8 9gs

Reference

None


About the buyer

Contact name

Lynne Nichols

Address

2nd Floor, Rutland House
Runcorn
WA7 2ES
GB

Email

lynne.nichols@dhsc.gov.uk